Search
Request a Quote

Scalable, high-titer recombinant protein production for clinical and commercial supply

High-Yield Heterologous Protein Production

Scalable, high-titer recombinant protein production for clinical and commercial supply

We deliver end-to-end expression and fermentation optimization for complex proteins, combining advanced strain engineering with process definition and analytical readiness. From host selection through scale-up documentation, our service is designed to help CMOs and biopharma firms establish robust production strains and reproducible yields for clinical and commercial programs. Our integrated approach addresses the genetic elements, fermentation conditions, and downstream recovery steps that together determine whether a high-yield strain delivers consistent, documented performance at production scale.

End-to-end expression and fermentation optimization
Advanced strain engineering for high-yield heterologous production
Process definition, risk mapping, and raw-material controls
Comparability and analytical readiness for scale-up
Documentation to support clinical and commercial supply

What is high-yield heterologous protein production?

Heterologous protein production uses a host organism—such as Komagataella phaffii (formerly Pichia pastoris), Escherichia coli, or other microbial systems—to express a protein encoded by a foreign gene. The approach is central to industrial biotechnology because it enables scalable, cost-effective synthesis of enzymes, therapeutic proteins, and industrial biocatalysts that are difficult to obtain from native sources.

Achieving high yields depends on more than inserting a gene into a host. Expression levels are governed by genetic elements—promoters, signal sequences, codon usage, and copy number—as well as by fermentation conditions, strain stability, and downstream recovery. Our service addresses each of these levers systematically, so that yield improvements achieved at the bench are preserved as the process scales.

For biopharma and contract manufacturing organizations, the goal is not just high titer in a shake flask but reproducible, documented performance in production-scale fermenters. We combine strain engineering with process definition and analytical readiness to help you move from construct to clinical or commercial supply with confidence.

Host selection

The right expression system for your protein

Different proteins place different demands on a host. We help you select among bacterial, yeast, and other systems based on your protein's complexity, post-translational modification needs, and production scale.

  • Bacterial systems for simple, disulfide-free proteins
  • Yeast systems such as K. phaffii for secreted and glycosylated proteins
  • High-cell-density fermentation for volumetric productivity
Strain engineering

Genetic elements that drive expression

Yield is determined at the genetic level. We engineer promoters, signal sequences, and codon usage to maximize expression of your target protein in the chosen host.

  • Promoter selection and optimization
  • Signal sequence design for secretion
  • Codon optimization for the host organism
Process optimization

Fermentation and scale-up definition

High-yield strains only deliver if the fermentation process is defined and controlled. We map process parameters, raw-material controls, and comparability to support reproducible scale-up.

  • Media and feed strategy definition
  • Process parameter mapping and risk assessment
  • Comparability documentation for scale-up

Why heterologous production matters

Recombinant protein production in bacteria and yeast is pivotal in industrial biotechnology, enabling scalable, cost-effective, and efficient synthesis of proteins that are otherwise difficult to obtain. For therapeutic proteins, CHO cells and E. coli together account for the vast majority of new target proteins, with each system offering distinct advantages depending on the protein's complexity and required post-translational modifications.

Yeast systems such as K. phaffii have emerged as particularly attractive for high-yield heterologous protein production. They combine high folding efficiency, the ability to reach high cell densities in defined media, and strong, tightly regulated promoters—features that translate to high volumetric productivity and simplified downstream processing.

For industrial enzymes and other non-therapeutic proteins, microbial systems offer a compelling balance of yield, speed, and scalability. The choice of host and the engineering strategy must be matched to the protein's structural complexity, intended application, and production scale.

Host system Key strengths Typical applications Considerations
E. coli Fast growth, simple media, well-characterized genetics Enzymes, antibody fragments, proteins without glycosylation Inclusion body formation, limited post-translational modifications
K. phaffii (P. pastoris) High cell density, strong promoters, protein secretion Secreted enzymes, therapeutic proteins, industrial biocatalysts Glycosylation pattern differs from mammalian cells
CHO cells Human-like post-translational modifications Monoclonal antibodies, complex therapeutic proteins Lower volumetric productivity, higher cost
Other microbial hosts Specialized pathways, unique product profiles Secondary metabolites, complex natural products Host-specific engineering requirements

How our service works

Our engagement follows a structured path from construct design to scale-up documentation. Each phase is designed to build on the previous one, so that decisions made early—host selection, genetic element choice—are validated and de-risked before larger investments in fermentation and downstream work.

1

Construct design and host selection

We begin by reviewing your target protein's structure, complexity, and intended application. Based on this assessment, we select the most appropriate host and design the expression construct, including promoter, signal sequence, and codon optimization tailored to the host organism.

2

Strain engineering and screening

The expression construct is introduced into the host, and resulting strains are screened for expression level, stability, and product quality. Lead candidates are identified based on titer, secretion efficiency, and growth characteristics in defined media.

3

Fermentation process definition

We define the fermentation process for lead strains, including media composition, feed strategy, and process parameters. This phase establishes the conditions that will support reproducible, high-yield production at scale.

4

Scale-up and comparability

The defined process is transferred to larger-scale equipment, with comparability assessed across scales. We document process performance, product quality attributes, and any adjustments required to maintain yield and quality.

5

Analytical readiness and documentation

We deliver a complete documentation package covering process definition, risk mapping, raw-material controls, and analytical methods. This package is designed to support your regulatory and supply-chain requirements for clinical or commercial production.

Customization and differentiators

Every protein program has unique requirements. Our service is designed to be tailored to your specific target, host, and scale—not delivered as a one-size-fits-all package. We combine deep expertise in genetic element engineering with practical fermentation knowledge to address the challenges that typically limit yield.

Our approach is distinguished by its focus on the full production path—from the genetic construct through to scale-up documentation. This end-to-end perspective ensures that yield improvements are not lost in translation between the lab and the production floor.

Genetic element engineering

Promoters, signal sequences, and codon optimization

We engineer the genetic elements that control expression, tailoring them to your target protein and host. This includes promoter selection, signal sequence design for secretion, and codon optimization for the production organism.

  • Strong, regulated promoters for controlled expression
  • Signal sequences designed for efficient secretion
  • Codon optimization matched to host tRNA pools
Strain development

Screening and selection of production strains

We generate and screen multiple strains to identify those with the best combination of titer, stability, and product quality. Lead candidates are characterized for growth and expression performance.

  • Multiple construct variants screened per program
  • Stability assessment over generation number
  • Product quality characterization for lead strains
Process definition

Fermentation and scale-up support

We define fermentation processes that support high-yield production, including media, feed strategy, and process parameters. Our documentation supports comparability as the process moves to larger scales.

  • Defined media and feed strategies
  • Process parameter mapping and risk assessment
  • Comparability documentation across scales

Applications and use cases

High-yield heterologous protein production serves a wide range of applications, from therapeutic proteins to industrial enzymes and specialty chemicals. The choice of host and engineering strategy depends on the protein's complexity, required modifications, and production scale.

For therapeutic proteins, the production system must deliver consistent quality and meet regulatory expectations. For industrial enzymes, the priorities are often volumetric productivity, cost efficiency, and the ability to operate at large scale. Our service is structured to address both sets of requirements.

Application Typical host Key requirements Our support
Therapeutic enzymes K. phaffii, CHO High purity, consistent quality, regulatory documentation Strain engineering, process definition, analytical readiness
Industrial enzymes E. coli, K. phaffii High volumetric productivity, cost efficiency, scale-up High-cell-density fermentation, process optimization
Antibody fragments E. coli Proper folding, high yield, low endotoxin Construct design, strain screening, fermentation definition
Specialty chemicals Engineered microbial hosts Pathway optimization, product yield, scalability Host engineering, process scale-up, documentation

Quality and documentation

For clinical and commercial supply, documentation is as important as yield. We provide a comprehensive package that covers process definition, risk mapping, raw-material controls, and analytical methods—designed to support your regulatory and supply-chain requirements.

Our documentation approach is built around comparability: demonstrating that the process performs consistently across scales and batches. This is essential for transferring a process from development to production and for maintaining product quality over time.

Process definition

Documented fermentation parameters

We document the fermentation process in detail, including media composition, feed strategy, and process parameters. This provides the foundation for reproducible production and scale-up.

  • Defined media and feed strategies
  • Process parameter ranges and setpoints
  • Batch record templates for production
Risk mapping

Identification of critical process parameters

We map process risks and identify critical parameters that affect yield and quality. This supports a risk-based approach to process control and scale-up.

  • Critical process parameter identification
  • Risk assessment for scale-up
  • Mitigation strategies for identified risks
Analytical readiness

Methods for product characterization

We provide analytical methods for product characterization, including purity, activity, and identity assays. This supports quality control and comparability assessments.

  • Purity and activity assays
  • Product identity confirmation
  • Comparability data across scales

Comparison with alternative approaches

Several strategies exist for producing recombinant proteins, each with distinct trade-offs. Our service focuses on the integrated approach—combining strain engineering with process definition—to address the limitations of simpler, one-dimensional strategies.

The table below compares our integrated service with common alternatives, highlighting where each approach is best suited and where it may fall short.

Approach Strengths Limitations Best suited for
Integrated strain + process service End-to-end optimization, documented scale-up, risk mapping Requires deeper engagement and longer timeline Clinical and commercial supply programs
Construct-only service Fast, low-cost, focused on genetic design No fermentation optimization, yield may not scale Early-stage research and feasibility
Off-the-shelf expression systems Standardized, well-characterized, easy to use Limited customization, may not address specific protein challenges Common proteins with established production routes
In-house development Full control, internal IP, tailored to internal needs Requires specialized expertise and infrastructure Organizations with established protein production capabilities

Why choose our service

Our service is built on a deep understanding of the genetic elements and strain engineering strategies that drive high-yield heterologous protein production. We combine this molecular-level expertise with practical fermentation knowledge to deliver results that hold up at scale.

We work as an extension of your team, providing the specialized expertise needed to overcome production bottlenecks. Our goal is to help you establish robust, reproducible production processes that support your clinical and commercial objectives.

Expertise

Deep knowledge of expression systems

Our team has extensive experience with bacterial and yeast expression systems, including K. phaffii, and understands the genetic levers that control yield.

  • Genetic element engineering expertise
  • Experience with multiple host systems
  • Knowledge of high-cell-density fermentation
Integration

End-to-end service from construct to scale-up

We cover the full production path, ensuring that yield improvements at the bench are preserved through fermentation and scale-up.

  • Construct design through process definition
  • Comparability documentation across scales
  • Analytical readiness for quality control
Documentation

Comprehensive support for regulatory needs

We provide documentation designed to support clinical and commercial supply, including process definition, risk mapping, and raw-material controls.

  • Process parameter documentation
  • Risk assessment and mitigation
  • Comparability and analytical data

Deliverables and support

Our service delivers a complete package designed to support your transition to clinical or commercial production. The specific deliverables are tailored to your program's needs and stage of development.

Support arrangements are confirmed with our customer service team to match your program's requirements.

FAQ

Which host system is right for my protein?

The choice of host depends on your protein's complexity, required post-translational modifications, and production scale. Bacterial systems such as E. coli are well-suited for simple proteins and offer fast growth and simple media. Yeast systems such as K. phaffii provide high cell density, strong promoters, and protein secretion, making them attractive for secreted enzymes and therapeutic proteins. We assess your target protein's characteristics and recommend the most appropriate host.

How do you ensure yields achieved in development are maintained at scale?

We address this through process definition and comparability documentation. The fermentation process is defined with specific media, feed strategy, and process parameters. As the process is transferred to larger scales, we assess comparability of performance and product quality, documenting any adjustments required. This approach is designed to preserve yield and quality from development through production.

What documentation do you provide for regulatory submissions?

We provide a comprehensive documentation package covering process definition, risk mapping, raw-material controls, and analytical methods. This includes documented fermentation parameters, critical process parameter identification, and comparability data across scales. The package is designed to support your regulatory and supply-chain requirements for clinical or commercial production.

Can you work with our existing strain or process?

Yes. We can engage at different points in the production path, including optimizing an existing strain or process. Our team can assess your current system, identify bottlenecks, and recommend improvements to genetic elements, fermentation conditions, or scale-up strategy. The specific engagement model is confirmed with our customer service team based on your program's needs.

What types of proteins have you produced?

Our service covers a range of protein types, including therapeutic enzymes, industrial enzymes, antibody fragments, and specialty chemicals. The production strategy is tailored to the protein's structural complexity and intended application. For each program, we select the host and engineering approach best suited to the target protein's requirements.

References

  1. Han L, Chen Q, Luo J. Development of a Glycerol-Inducible Expression System for High-Yield Heterologous Protein Production in Bacillus subtilis. Microbiol Spectr 2022 Oct 26. View on PubMed
  2. Meng L, Gao X, Liu X. Enhancement of heterologous protein production in Corynebacterium glutamicum via atmospheric and room temperature plasma mutagenesis and high-throughput screening. J Biotechnol 2021 Sep 20. View on PubMed
  3. by M Tsuda · 2024 · Cited by 34 — The advantages of the K. Recent progress on heterologous protein production in ... - PMC. phaffii production system comprise high folding efficiency, high-cell-density fermentation, a strong and highly ... View article
  4. Romsuk J, Yasumoto S, Fukushima EO. High-yield bioactive triterpenoid production by heterologous expression in Nicotiana benthamiana using the Tsukuba system. Front Plant Sci 2022. View on PubMed
  5. Fan Q, Caserta G, Lorent C. High-Yield Production of Catalytically Active Regulatory [NiFe]-Hydrogenase From Cupriavidus necator in Escherichia coli. Front Microbiol 2022. View on PubMed
  6. Gong K, Wang M, Duan Q. High-yield production of FK228 and new derivatives in a Burkholderia chassis. Metab Eng 2023 Jan. View on PubMed
  7. Wu Y, Zheng S, Yang Z. Integrated protein and metabolic engineering enable high-yield biosynthesis of resveratrol derivatives in Yarrowia lipolytica. Synth Syst Biotechnol 2025 Dec. View on PubMed
  8. Zhou Y, Zhao X, Zhao X. Evolution-guided high yield production of potent Gα(q/11)-signalling inhibitors FR900359 and YM-254890. Metab Eng 2026 Sep. View on PubMed

Ready to optimize your protein production?

Contact our team to discuss your target protein, production goals, and how our high-yield heterologous protein production service can support your program. We'll work with you to define the right approach for your specific needs.

Contact us

Online Inquiry

For research and industrial use only, not for personal medicinal use.

Submit